Immune-related adverse events caused by treatment with pembrolizumab in a patient with lung cancer who infected influenza virus

A 67-year-old man with stage IV B lung adenocarcinoma was treated with pembrolizumab. The patient was admitted to the hospital because of influenza on the day of the second cycle of pembrolizumab treatment. He was diagnosed with pneumonia and was treated with antiviral drugs and steroids. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Takemura, Masao, Motegi, Mitsuru, Kuroiwa, Yuya, Itai, Miki, Taguchi, Kohei, Umetsu, Kazue, Uchida, Megumi, Kounoc, Shunichi, Sato, Mari, Masubuchi, Hiroaki, Yamaguchi, Aya, Yamaguchi, Koichi, Ikeda, Kana, Nakagawa, Junichi, Maeno, Toshitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892985/
https://www.ncbi.nlm.nih.gov/pubmed/33643837
http://dx.doi.org/10.1016/j.rmcr.2021.101361

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7892985/
https://www.ncbi.nlm.nih.gov/pubmed/33643837
http://dx.doi.org/10.1016/j.rmcr.2021.101361

Ejemplares similares